Detailed Abstract
[BP Oral Presentation 3]
[BP OP 3-4] Circulating Tumor Cells with Epithelial-Mesenchymal Transition Features Predict Metastatic Outcome in Pancreatic Cancer
Xudong ZHAO1, Xiu DONG2, Yongsu MA1, Xiaodong TIAN1, Xiaohang ZHAO2, Yinmo YANG* 1
1Department of surgery, Peking University First Hospital, China
2State Key Laboratory of Molecular Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, China
Introduction : To clarify the metastatic potential of CTCs with mesenchymal phenotypic (mCTCs) characteristic in pancreatic cancer (PC).
Methods : Among both localized (n=21) and metastatic (n=14) patient populations, blood samples (7.5ml each) were drawn from peripheral vein. Of them, portal and peripheral blood samples were simultaneously collected intra operatively in 19 patients following surgical dissection prior to tumor removal. All samples were analyzed for CTCs with immunomagetic negative enrichment together with 4-channel immunofluorescence against Cytokeratin, Vimentin, DAPI and CD45.
Results : CTCs were detected in 91.4% (32/35) and 100.0% (14/14) of patients with AJCC stage Ⅰ-Ⅲ and stage Ⅳ tumors, respectively. 21 localized patients had a mean count of (148.9±159.9) CTCs/7.5 mL in peripheral blood, compared with a mean count of (279.5±297.5) CTCs/7.5 mL in 14 metastatic patients (p=0.127). Meanwhile, the mCTCs percentage tended to be higher in metastatic group, implying that mCTCs may be a risk factor for metastatic disease. Among 19 patients received operations, there was a mean count of (148.1±152.8) CTCs/7.5 mL in peripheral blood vs. (252.0.4±220.9) CTCs/7.5 mL in portal vein (p=0.170). However, the mCTCs percentage of portal vein was significantly different from that of peripheral vein (p=0.048), meaning a obvious spatial heterogeneity in epithelial and mesenchymal composition during circulation. The clinical significance of distant composition warrants further exploration.
Conclusions : CTCs with mesenchymal phenotype may in part represent tumor clones with high metastatic potential, suggesting that this special subtype CTC-positivity identifies patients with occult systemic disease and neoadjuvant therapy may improve the prognosis.
M2, In
Methods : Among both localized (n=21) and metastatic (n=14) patient populations, blood samples (7.5ml each) were drawn from peripheral vein. Of them, portal and peripheral blood samples were simultaneously collected intra operatively in 19 patients following surgical dissection prior to tumor removal. All samples were analyzed for CTCs with immunomagetic negative enrichment together with 4-channel immunofluorescence against Cytokeratin, Vimentin, DAPI and CD45.
Results : CTCs were detected in 91.4% (32/35) and 100.0% (14/14) of patients with AJCC stage Ⅰ-Ⅲ and stage Ⅳ tumors, respectively. 21 localized patients had a mean count of (148.9±159.9) CTCs/7.5 mL in peripheral blood, compared with a mean count of (279.5±297.5) CTCs/7.5 mL in 14 metastatic patients (p=0.127). Meanwhile, the mCTCs percentage tended to be higher in metastatic group, implying that mCTCs may be a risk factor for metastatic disease. Among 19 patients received operations, there was a mean count of (148.1±152.8) CTCs/7.5 mL in peripheral blood vs. (252.0.4±220.9) CTCs/7.5 mL in portal vein (p=0.170). However, the mCTCs percentage of portal vein was significantly different from that of peripheral vein (p=0.048), meaning a obvious spatial heterogeneity in epithelial and mesenchymal composition during circulation. The clinical significance of distant composition warrants further exploration.
Conclusions : CTCs with mesenchymal phenotype may in part represent tumor clones with high metastatic potential, suggesting that this special subtype CTC-positivity identifies patients with occult systemic disease and neoadjuvant therapy may improve the prognosis.
M2, In
SESSION
BP Oral Presentation 3
Room C 4/5/2019 4:01 PM - 4:08 PM